publication date: Oct. 12, 2018

In Brief

Cancer biologist Steven Artandi to lead Stanford Cancer Institute, replacing outgoing director Beverly Mitchell

Steven Artandi, professor of medicine and of biochemistry at the School of Medicine, was named director of the Stanford Cancer Institute effective Oct. 1.

Artandi replaces Beverly Mitchell, who has served as director for the past 10 years. Mitchell, a professor of medicine, will continue her involvement with the institute as senior adviser, researcher and mentor.

“A strategic thinker and collaborative physician-scientist, Dr. Artandi’s understanding of the opportunities to develop synergies between the elements of our tripartite mission — excellence in research, patient care and education — make him uniquely qualified to further the SCI’s goal of translating Stanford discoveries into individualized cancer care,” Lloyd Minor, dean of the School of Medicine, said in a statement. “His work is already producing new insights into the origins of cancer, revealing how aspiring cancers circumvent critical bottlenecks encountered during carcinogenesis, and leading to new therapies with the potential to treat many of the most refractory human cancers.”

Artandi, who holds the Jerome and Daisy Low Gilbert Professorship, is a cancer biologist whose research focuses on the role played by the enzyme telomerase in cancer, aging, and stem cell biology.

“I’m very honored to be the next director of the Stanford Cancer Institute, particularly at this exciting juncture in the history of cancer research and cancer therapy,” Artandi said in a statement. “We are entering a period during which major translational discoveries will transform our approach to treating cancer patients. Stanford has remarkable strengths in innovation, basic science, clinical medicine and translation. We’re also fortunate to have extraordinary people, including faculty, trainees, nurses and … Continue reading Cancer biologist Steven Artandi to lead Stanford Cancer Institute, replacing outgoing director Beverly Mitchell

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2019 The Cancer Letter Inc.